Literature DB >> 25472952

Epigenetics in the hematologic malignancies.

Chun Yew Fong1, Jessica Morison2, Mark A Dawson3.   

Abstract

A wealth of genomic and epigenomic data has identified abnormal regulation of epigenetic processes as a prominent theme in hematologic malignancies. Recurrent somatic alterations in myeloid malignancies of key proteins involved in DNA methylation, post-translational histone modification and chromatin remodeling have highlighted the importance of epigenetic regulation of gene expression in the initiation and maintenance of various malignancies. The rational use of targeted epigenetic therapies requires a thorough understanding of the underlying mechanisms of malignant transformation driven by aberrant epigenetic regulators. In this review we provide an overview of the major protagonists in epigenetic regulation, their aberrant role in myeloid malignancies, prognostic significance and potential for therapeutic targeting. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh：

Year:  2014        PMID： 25472952      PMCID： PMC4258753          DOI： 10.3324/haematol.2013.092007

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  186 in total

1.  Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies.

Authors:  Leonie I Kroeze; Gorica Nikoloski; Pedro da Silva-Coelho; Patricia van Hoogen; Ellen Stevens-Linders; Roland P Kuiper; Susanne Schnittger; Torsten Haferlach; Heike L Pahl; Bert A van der Reijden; Joop H Jansen
Journal:  Blood       Date:  2012-02-02       Impact factor: 22.113

2.  Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications.

Authors:  Thomas A Milne; Mary Ellen Martin; Hugh W Brock; Robert K Slany; Jay L Hess
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

Review 3.  The promise and failures of epigenetic therapies for cancer treatment.

Authors:  Pasano Bojang; Kenneth S Ramos
Journal:  Cancer Treat Rev       Date:  2013-07-05       Impact factor: 12.111

Review 4.  The super elongation complex (SEC) family in transcriptional control.

Authors:  Zhuojuan Luo; Chengqi Lin; Ali Shilatifard
Journal:  Nat Rev Mol Cell Biol       Date:  2012-08-16       Impact factor: 94.444

5.  The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.

Authors:  David A Russler-Germain; David H Spencer; Margaret A Young; Tamara L Lamprecht; Christopher A Miller; Robert Fulton; Matthew R Meyer; Petra Erdmann-Gilmore; R Reid Townsend; Richard K Wilson; Timothy J Ley
Journal:  Cancer Cell       Date:  2014-03-20       Impact factor: 31.743

6.  Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome.

Authors:  Nathaniel D Heintzman; Rhona K Stuart; Gary Hon; Yutao Fu; Christina W Ching; R David Hawkins; Leah O Barrera; Sara Van Calcar; Chunxu Qu; Keith A Ching; Wei Wang; Zhiping Weng; Roland D Green; Gregory E Crawford; Bing Ren
Journal:  Nat Genet       Date:  2007-02-04       Impact factor: 38.330

7.  Clonal inheritance of the pattern of DNA methylation in mouse cells.

Authors:  R Stein; Y Gruenbaum; Y Pollack; A Razin; H Cedar
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

8.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

9.  A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.

Authors:  Laurens Kruidenier; Chun-wa Chung; Zhongjun Cheng; John Liddle; KaHing Che; Gerard Joberty; Marcus Bantscheff; Chas Bountra; Angela Bridges; Hawa Diallo; Dirk Eberhard; Sue Hutchinson; Emma Jones; Roy Katso; Melanie Leveridge; Palwinder K Mander; Julie Mosley; Cesar Ramirez-Molina; Paul Rowland; Christopher J Schofield; Robert J Sheppard; Julia E Smith; Catherine Swales; Robert Tanner; Pamela Thomas; Anthony Tumber; Gerard Drewes; Udo Oppermann; Dinshaw J Patel; Kevin Lee; David M Wilson
Journal:  Nature       Date:  2012-08-16       Impact factor: 49.962

10.  High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction.

Authors:  Shihan He; Timothy J Senter; Jonathan Pollock; Changho Han; Sunil Kumar Upadhyay; Trupta Purohit; Rocco D Gogliotti; Craig W Lindsley; Tomasz Cierpicki; Shaun R Stauffer; Jolanta Grembecka
Journal:  J Med Chem       Date:  2014-02-06       Impact factor: 7.446
View more
  23 in total

Review 1.  A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia.

Authors:  Anuradha Kirtonia; Gouri Pandya; Gautam Sethi; Amit Kumar Pandey; Bhudev C Das; Manoj Garg
Journal:  J Mol Med (Berl)       Date:  2020-07-03       Impact factor: 4.599

2.  GPX3 promoter is methylated in chronic myeloid leukemia.

Authors:  Dong-Ming Yao; Jing-Dong Zhou; Ying-Ying Zhang; Lei Yang; Xiang-Mei Wen; Jing Yang; Hong Guo; Qin Chen; Jiang Lin; Jun Qian
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

3.  Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms.

Authors:  Maria Kleppe; Richard Koche; Lihua Zou; Peter van Galen; Corinne E Hill; Lauren Dong; Sofie De Groote; Efthymia Papalexi; Amritha V Hanasoge Somasundara; Keith Cordner; Matthew Keller; Noushin Farnoud; Juan Medina; Erin McGovern; Jaime Reyes; Justin Roberts; Matthew Witkin; Franck Rapaport; Julie Teruya-Feldstein; Jun Qi; Raajit Rampal; Bradley E Bernstein; James E Bradner; Ross L Levine
Journal:  Cancer Cell       Date:  2017-12-14       Impact factor: 31.743

4.  BPTF promotes tumor growth and predicts poor prognosis in lung adenocarcinomas.

Authors:  Meng Dai; Jian-Jun Lu; Wei Guo; Wendan Yu; Qimin Wang; Ranran Tang; Zhipeng Tang; Yao Xiao; Zhenglin Li; Wei Sun; Xiuna Sun; Yu Qin; Wenlin Huang; Wu-guo Deng; Taihua Wu
Journal:  Oncotarget       Date:  2015-10-20

Review 5.  Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies.

Authors:  Elisabetta Fratta; Barbara Montico; Aurora Rizzo; Francesca Colizzi; Luca Sigalotti; Riccardo Dolcetti
Journal:  Oncotarget       Date:  2016-08-30

6.  Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.

Authors:  Katarina Lyberg; Hani Abdulkadir Ali; Jennine Grootens; Matilda Kjellander; Malin Tirfing; Michel Arock; Hans Hägglund; Gunnar Nilsson; Johanna Ungerstedt
Journal:  Oncotarget       Date:  2017-02-07

7.  Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.

Authors:  Chengyin Min; Nathan Moore; Jeffrey R Shearstone; Steven N Quayle; Pengyu Huang; John H van Duzer; Matthew B Jarpe; Simon S Jones; Min Yang
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

8.  Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.

Authors:  M N Cruickshank; J Ford; L C Cheung; J Heng; S Singh; J Wells; T W Failes; G M Arndt; N Smithers; R K Prinjha; D Anderson; K W Carter; A M Gout; T Lassmann; J O'Reilly; C H Cole; R S Kotecha; U R Kees
Journal:  Leukemia       Date:  2016-06-13       Impact factor: 11.528

9.  Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy.

Authors:  Christine S Young; Kathryn M Clarke; Laura M Kettyle; Alexander Thompson; Ken I Mills
Journal:  Oncotarget       Date:  2017-05-19

10.  An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy.

Authors:  Vanessa Szablewski; Caroline Bret; Alboukadel Kassambara; Julie Devin; Guillaume Cartron; Valérie Costes-Martineau; Jérôme Moreaux
Journal:  Oncotarget       Date:  2018-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.